Early Management of Acute Ischemic Stroke: Focus on IV tPA and Timely Reperfusion
Alteplase (Activase), an intravenous (IV) tissue plasminogen activator (tPA), is the only FDA-approved thrombolytic agent for acute ischemic stroke (AIS). Recently updated American Heart Association/American Stroke Association (AHA/ASA) Guidelines for the Early Management of Patients with Acute Ischemic Stroke and revisions to Activase labeling have expanded the time window eligibility for tPA treatment and have loosened contraindications surrounding tPA treatment. These changes should promote increased utilization of tPA in AIS, resulting in more instances of timely reperfusion and reduction of neurologic sequelae.
Nguyen, VV, Wong BM, Shen DD, Woo DT, Vu AV, Lie JD. Early management of acute ischemic stroke: focus on IV tPA and timely reperfusion. US Pharm. 2016;41(1):HS9-H12. http://www.uspharmacist.com/content/c/59017/.
Jobson Medical Information LLC